Eisai And Pfizer Begin Undertaking To Switch Appropriate Patients To High-dose Aricept
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Eisai will launch a "substantial marketing campaign" behind the recent U.S. approval of high-dose Aricept (donepezil) as the company races to move moderate to severe Alzheimer's disease patients that could benefit from higher doses of the drug from the 10 mg dosage to the newly approved 23 mg dosage ahead of Aricept 10 mg's November 2010 patent loss
You may also be interested in...
Japan's Taisho Falters Under NHI Price Cuts; Eisai Squeezing Sales Out Of Aricept - Japanese Earnings Week
TOKYO - Taisho Pharmaceutical Co. said it operated in a difficult business environment in 2010, attributing weak sales to National Health Insurance price cuts and decreased demand for cold remedies
Japan's Taisho Falters Under NHI Price Cuts; Eisai Squeezing Sales Out Of Aricept - Japanese Earnings Week
TOKYO - Taisho Pharmaceutical Co. said it operated in a difficult business environment in 2010, attributing weak sales to National Health Insurance price cuts and decreased demand for cold remedies
Eisai Makes Oncology Debut With Halaven, But Development Question Marks Remain
TOKYO - Eisai gained its first U.S. approval for one of its in-house developed oncology products, Halaven (eribulin), but the company's blockbuster expectations may be tempered by progression-free survival data that did not meet secondary endpoints